Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 169 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Selpercatinib Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC MOST POPULAR NF1 Associated with More Cancer Types Than Previously Known April 20, 2021 EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... March 24, 2021 Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... January 5, 2021 Load more HOT NEWS What Happens If More People Get Screened for Cancer? Consensus on Conceptual Framework for Precision Cancer Medicine in Germany Targeting the Accomplice: A Potential Treatment Approach for Rhabdomyosarcoma New on NCI’s Websites for March 2022
